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Abstract
The relationship between inflammation and cancer is well established in several tumor types, including bladder cancer. We
performed an association study between 886 inflammatory-gene variants and bladder cancer risk in 1,047 cases and 988
controls from the Spanish Bladder Cancer (SBC)/EPICURO Study. A preliminary exploration with the widely used univariate
logistic regression approach did not identify any significant SNP after correcting for multiple testing. We further applied two
more comprehensive methods to capture the complexity of bladder cancer genetic susceptibility: Bayesian Threshold
LASSO (BTL), a regularized regression method, and AUC-Random Forest, a machine-learning algorithm. Both approaches
explore the joint effect of markers. BTL analysis identified a signature of 37 SNPs in 34 genes showing an association with
bladder cancer. AUC-RF detected an optimal predictive subset of 56 SNPs. 13 SNPs were identified by both methods in the
total population. Using resources from the Texas Bladder Cancer study we were able to replicate 30% of the SNPs assessed.
The associations between inflammatory SNPs and bladder cancer were reexamined among non-smokers to eliminate the
effect of tobacco, one of the strongest and most prevalent environmental risk factor for this tumor. A 9 SNP-signature was
detected by BTL. Here we report, for the first time, a set of SNP in inflammatory genes jointly associated with bladder cancer
risk. These results highlight the importance of the complex structure of genetic susceptibility associated with cancer risk.
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Introduction
Bladder cancer (BC) is the fifth most common neoplasm in
terms of incidence in industrialized countries accounting for
approximately 5–7% and 2–2.5% of the newly diagnosed
malignancies in men and women, respectively. BC is one of the
most prevalent cancers due to its chronic nature [1]. Tobacco and
occupational exposure to aromatic amines are the two best
established environmental risk factors [2,3]. In addition, strong
evidence for the influence of common genetic variants on BC
development has been acquired in the last years [4,5]. Genetic
susceptibility to BC has been investigated in relation to genes
encoding enzymes involved in the metabolism of xenobiotics,
apoptosis, cell cycle control, angiogenesis, and inflammation [4].
As for the latter process, there is evidence that inflammatory
cells, proinflammatory cytokines, and chemokines contribute to
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immunosuppression, cancer growth, and progression [6]. A link
between chronic inflammation and BC is supported by the
associations found between Schistosoma haematobium and squamous
cell carcinoma [7] and, less consistently, between urothelial cell
carcinoma and other types of urinary tract infection [8]. In
addition, the protective effect of long-term use of non-steroidal
anti-inflammatory drugs observed in some case-controls studies
supports a role of inflammation in this cancer [9,10].
Most association studies have focused on the detection of main
effects by using an allele- or genotype-based test for each single-
nucleotide polymorphism (SNP) separately. However, it is known
that complex traits, including BC, are explained by multiple loci
with rather small individual effects [11]. Thus, this simple strategy
will probably capture only a small proportion of the total genetic
variance of the disease conferred by all variants [12]. Therefore,
strategies to assess at the same time multiple SNPs and their
interaction effects are needed. Standard statistical methods such as
logistic regression are not well suited to this end. This level of
genetic complexity represents a statistical challenge in association
studies because of the high number of regression coefficients (p) in
comparison to sample size (n). Machine learning algorithms
provide alternatives for performing multi-SNP analysis [13]. These
algorithms are highly appealing since they are model specification-
free and may capture hidden information. Random Forest (RF), a
classification algorithm proposed by Breiman [14] that can be
used to identify the most important variables related to the disease,
has also been successfully applied to genome wide data [15].
Recently, an algorithm for variable selection has been proposed
(AUC-RF): it identifies the set of variables with the highest
predictive accuracy by optimizing the AUC (the area under the
ROC curve) of a sequence of random forests [16]. Other methods
to deal with oversaturated regression problems [17] that are
gaining recognition are the regularized regression methods, such
as ridge regression [18], the Least Absolute Shrinkage and
Selection Operator (LASSO) [19], and its Bayesian version [20].
These methods are penalized likelihood procedures where suitable
penalty functions are added to the negative log-likelihood to
automatically shrink spurious effects (effects of redundant covar-
iates) towards zero while effectively estimating the relevant ones.
The Bayesian version of LASSO provides several advantages over
ridge regression or the classical LASSO. As other Bayesian
models, it provides measures of uncertainty about estimates and
predictions, and as a consequence, valid standard errors, which
can be problematic for the frequentist LASSO [21]. In addition, it
yields marker-specific shrinkage of effect estimates, in contrast to
ridge regression, and overcomes the main limitation of LASSO
which admits at most n-1 nonzero regression coefficients [22].
Until present, whole genome association studies (GWAS)
individually analyzed a huge number of SNPs, most of them
located in regions not associated with the trait of interest while
others in LD with the causal variant. This approach is
unsatisfactory for traits affected by a large number of variants/
genes [12]. An alternative strategy is pathway analysis, dealing
with the joint assessment of a subset of SNPs with a potential
functional effect on the phenotype of interest.
The main objective of this study was to assess whether SNPs in
inflammation-related genes play a role in BC development in a
large case control study conducted in Spain and, subsequently, to
identify a pattern of those variants (signature) associated with the
BC risk by applying two recently developed statistical methods,
Bayesian threshold LASSO (BTL) model and AUC-RF. To assess
the robustness of the strategy, relevant findings were also analyzed
in an independent study, the Texas Bladder Cancer Study.
Results
Summary statistics
Table 1 shows the characteristics of cases and controls for the
whole sample and for the non-smoker subpopulation. Overall, the
study comprised 1,047 cases and 988 controls with genotyping
data for 886 SNPs in 194 inflammatory genes. The non-smoker
subset consisted of 424 individuals, 147 of which were BC cases.
The median age of patients at diagnosis was 68 and 70 years
(ranges 22–80 yrs) for the total population and non-smokers,
respectively. Overall, cigarette smoking was more common in
cases than in controls (86% vs. 72%) and in men than in women
(87% vs. 22%). Consequently, the percentage of men was different
in both sets of individuals: 87% and 35% for the total study and for
non-smokers, respectively.
Total population analysis
The application of the Bayesian Threshold LASSO provides for
each SNP its posterior probability of being associated with BC. In
Figure 1, we show the distribution of the posterior probability of
each SNP, ranked in decreasing order. SNPs were considered to
be associated to BC if the posterior probability of being higher/
lower than 0 was . 80%. This strategy identified 37 SNPs in 34
genes showing an association with BC. The highest posterior
probability (i.e., most relevant association) was 96.07% for CASP3-
rs3087455, whereas the lowest one was 51.98% for TLR2-
rs3804100. The SNPs with a protective minor allele were:
CASP3-rs3087455, CCR3-rs3091312, CASP9-rs2020902, IL17A-
rs8193036, MAP3K7-rs150126, IL6R-rs8192284, BLNK-
rs3789928, SCARB1-rs4765621, FOS-rs7101, TBK1-rs10878176,
BIRC5-rs744120, LY96-rs17226566, AICDA-rs11046349,
MAP2K4-rs4791489, IL15-rs17461269, CD14_IK-rs2569190,
JAK3-rs11888 and TNFRSF10A-rs4871857. The OR posterior
means ranged from 0.81 to 0.93 when comparing the minor with
the common homozygous genotypes (Table 2). The SNPs with the
minor allele associated with an increased risk of BC were: PRF1-
rs10999426, IL7R-rs1494555, ABCA1-rs2230806, IFNAR2-
rs2236757, MASP1-rs710459, BLNK-rs12357751, MAP3K3-
rs7209435, BLNK-rs10882755, TLR2-rs3804099, SOCS6-
rs723279, IL17C-rs899729, TLR4-rs2737191, FOS-rs1063169,
ABCC4-rs3765535, PARP4-rs13428, BIRC3-rs11602147, IL21R-
rs8049804, FADD-rs7939734 and ICAM1-rs5498. The posterior
means of ORs ranged from 1.10 to 1.20, when comparing the
minor with common homozygous genotypes. All the detected
SNPs were in Hardy-Weinberg equilibrium in the control
population. Single-SNP logistic regression models yielded p-values
,0.05 for 17 of them (of a total of 32, see Table S1) with a
minimum p-value of 0.0021, not corrected by multiple testing. The
estimated OR corresponding to the 37 SNPs-signature was .4.92
(see Figures S1 and S2 for more details). The 95% interval for the
OR when comparing the highest risk genotype combination with
the highest protective one ranged from 31.2–629.4. The wide
range of the credibility interval shows the large error associated
with the estimate. Posterior mean, median and mode of the
asymmetric posterior distribution were 206.5, 123.5 and 63.8,
respectively.
AUC-RF considered both genetic and non-genetic variables
and detected an optimal subset of 59 factors, including 56 SNPs
(Table S2). All the environmental covariates, except for gender,
were ranked first: smoking status was ranked as the most relevant
variable, with a Mean Decrease Gini index (MDG) of 11.55,
followed by geographical region with a relative importance of
35.2%. The age of the patient was ranked in the third place with a
relative importance of 19.4%, followed by SNPs. Table 3 shows
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the 12 most important SNPs detected by this method. Their
relative importance ranged from 20.8% for JAK3-rs2286662 to
14.4% for AKR1C3-rs1937845.
Thirteen SNPs in CASP3, PRF1, IL7R, ABCA1, IL6R, MASP1,
SCARB1, TLR2, IL17C, MAP2K4, CD14_IK, FADD, and ICAM1
were identified as relevant by both BTL and AUC-RF
approaches (bold-faced SNPs in Table 2; see also Figure 2a.).
Among them, 6 SNPs located in CASP3, PRF1, IL7R, ABCA1,
IL6R and CD14_IK had a p-value,0.05 by logistic regression
adjusted by covariates (see Table 2, for more details). The
significance of none of them held after Bonferroni correction for
multiple testing [23]. Despite the fact that no significant
association was found after performing the single marker
analyses, the ranking of SNPs highly correlated with that
obtained from the posterior probability BTL-based results
(Spearman’s correlation, rho = 0.78).
Genotypes for 17/37 SNPs with a posterior probability higher
than 80% in the discovery phase were available from the TXBC
study and this information was used for replication purposes. In
addition, 13 SNPs in high LD with SNPs detected by BTL in
the discovery phase were included in the phase 2 analyses.
Table S3 shows the posterior probabilities of being larger/
smaller than 0 and the posterior mean of ORs obtained in the
replication set. Two SNPs (IL6R-rs4129267 and TBK1-
rs10878182) in high LD with IL6R-rs8192284 and TBK1-
rs10878176 detected in the discovery study by BTL had
posterior probabilities of having a non-null effect higher than
90%. The OR of these surrogate SNPs were of risk while those
identified in the discovery study were of protection. Five
additional SNPs (IL21R-rs9930086 - in high LD with IL21R-
rs8049804, and MAP3K3-rs7209435, IL17A-rs8193036, FADD-
rs7939734, and TLR2-rs3804099) showed posterior probabilities
.70%, the threshold considered for replication. The ORs of
these 5 SNPs were of the same magnitude and direction as those
found in the discovery study.
Non-smoker subset analysis
Tobacco smoking is the strongest and most prevalent environ-
mental risk factor for BC and it may modify the effect of SNPs in
inflammation-related genes. Therefore, we performed the
association analysis among non-smokers to bypass its effect. In
such a context, BTL detected only two relevant SNPs (BCL10-
2647396 and NFKBIA-rs696) associated with the risk of BC with
a posterior probability of at least 80%. The two SNPs were also
detected by AUC-RF (see Figure 2b). When we extended the
posterior probability ($75%), the number of SNPs detected by
both approaches increased up to 8 in 8 genes (see Table 4). OR
posterior means ranged from 1.12–1.16 for those SNPs showing
an increased risk of BC, when comparing the two homozygous
genotypes, and from 0.89–0.91 for those with a protective
effect. Univariate logistic regression analysis yielded significant
results for the 8 SNPs with a minimum p-value of 0.0032, not
corrected by multiple testing. The OR median posterior density
corresponding to the 9 SNPs-signature detected by BTL was
2.73, with a posterior probability of 99% of being .1 and a
range between 1.35 and 6.66 as 95% credible interval (see
Figure S3).
AUC-RF detected an optimal subset of 93 variables related to
BC, 90 of which were SNPs (Table S4). Contrary to the findings in
the total population, gender was the most important covariate
related to BC among non-smokers, and age and region were at the
third and fourth position, respectively.
Common SNPs between total and non-smoker datasets
Figures 2c and 2d show the number of SNPs detected by both
BTL and AUC-RF in the SBC/EPICURO study for both the
whole population and the non-smoker individuals. There were no
common SNPs detected by BTL for those population sets with
posterior probabilities greater than 80%. However, when the
posterior probability applied was $75%, three SNPs were
detected in both datasets: MAP2K4-rs4791489, PRF1-rs10999426
and BCL10-rs2647396.
Table 1. Characteristic profile of the studied population.
Total population Non-smoker subset
Cases Controls Cases Controls
n = 1047 (%) n = 988 % n = 147 % n = 277 %
Gender
Male 915 (87) 873 (88) 52 (35) 180 (65)
Female 132 (13) 115 (12) 95 (65) 97 (35)
Smoking status
Never smokers 147 (14) 277 (28) 147 (100) 277 (100)
Occasional
smokers
44 (4) 79 (8)
Former smokers 400 (38) 361 (37)
Current smokers 450 (43) 267 (27)
Geographical area
Barcelona 182 (17) 196 (20) 22 (15) 45 (16)
Valle`s/Bages 171 (16) 157 (16) 21 (14) 38 (14)
Elche 77 (7) 79 (8) 15 (10) 27 (10)
Asturias 180 (17) 146 (15) 26 (18) 35 (13)
Tenerife 437 (42) 410 (41) 63 (43) 132 (48)
doi:10.1371/journal.pone.0083745.t001
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Table 2. Risk estimates of Bayesian Threshold LASSO model (BTL), considering a posterior probability higher than 80%, and from
logistic regression for the total population.
SNP Gene Type Position Alleles ORaa_AA
a
Post
probb ORaa_AA
c p-valued
rs3087455 CASP3 Intronic 4q35.1 A/C 0.81 96.07 0.66 0.002
rs10999426 PRF1 Intronic 10q22.1 A/G 1.20 93.33 1.36 0.025
rs1494555 IL7R non_synonymous
coding
5p13.2 G/A 1.19 92.30 1.43 0.015
rs2230806 ABCA1 non_synonymous
coding
9q31.1 G/A 1.19 92.05 1.38 0.029
rs3091312 CCR3 downstream 3p21.31 A/T 0.86 90.93 0.69 0.013
rs8192284 IL6R non_synonymous
coding
1q21.3 A/G 0.88 90.35 0.74 0.022
rs2236757 IFNAR2 intronic 21q22.11 A/G 1.16 89.77 1.43 0.015
rs8193036 IL17A upstream 6p12.2 C/T 0.88 88.50 0.74 0.048
rs710459 MASP1 intronic 3q27.3 C/T 1.14 88.17 1.23 0.113
rs4765621 SCARB1 intronic 12q24.31 G/A 0.89 87.88 0.78 0.063
rs150126 MAP3K7 intronic 6q15 G/A 0.88 87.74 0.68 0.011
rs3789928 BLNK intronic 10q24.1 G/C 0.88 87.63 0.78 0.069
rs7209435 MAP3K3 intronic 17q23.3 T/C 1.13 86.29 1.29 0.095
rs2020902 CASP9 splice site 1p36.21 T/C 0.88 86.19 0.61 0.007
rs899729 IL17C upstream 16q24.3 C/A 1.12 86.06 1.22 0.132
rs7101 FOS 5’ UTR 14q24.3 C/T 0.89 85.93 0.71 0.023
rs12357751 BLNK intronic 10q24.1 C/T 1.14 85.67 1.36 0.040
rs3804099 TLR2 synonymous coding 4q31.1 T/C 1.13 84.97 1.27 0.072
rs2737191 TLR4 upstream 9q33.1 A/G 1.12 84.53 1.28 0.088
rs4791489 MAP2K4 downstream 17p12 C/T 0.91 84.52 0.80 0.112
rs10878176 TBK1 intronic 12q14.2 G/C 0.90 83.88 0.70 0.014
rs17226566 LY96 intronic 8q21.11 T/C 0.90 83.47 0.77 0.108
rs744120 BIRC5 upstream 17q25.3 C/G 0.90 83.27 0.69 0.014
rs723279 SOCS6 intronic 18q22.2 G/A 1.12 83.16 1.28 0.097
rs13428 PARP4 non_synonymous
coding
13q12.12 G/C 1.11 83.11 1.26 0.094
rs11046349 AICDA 3’ UTR 12p13.31 T/G 0.91 82.17 0.60 0.014
rs11602147 BIRC3 intronic 11q22.2 C/G 1.10 81.98 1.23 0.148
rs1063169 FOS intronic 14q24.3 G/T 1.12 81.88 1.56 0.018
rs2569190 CD14_IK 5’ UTR 5q31.3 A/G 0.92 81.83 0.75 0.025
rs5498 ICAM1 coding unknown 19q13.2 HGMD
mutation
1.10 81.24 1.25 0.087
rs17461269 IL15 intronic 4q31.21 T/A 0.91 81.22 0.76 0.072
rs3765535 ABCC4 intronic 13q32.1 A/G 1.12 81.21 1.41 0.091
rs11888 JAK3 3’ UTR 19p13.11 T/C 0.92 81.15 0.84 0.212
rs10882755 BLNK intronic 10q24.1 A/G 1.13 80.76 1.41 0.058
rs7939734 FADD upstream 11q13.3 T/A 1.10 80.75 1.22 0.135
rs8049804 IL21R intergenic 17q22 A/C 1.10 80.33 1.18 0.239
rs4871857 TNFRSF10A non synonymous coding 8p21.3 G/C 0.93 80.22 0.80 0.082
aPosterior mean of the OR, calculated from the BTL analyses Similar values for the median were obtained for each SNP.
bIt corresponds to max a, 1{að Þf gw0:8, where a~
ðz?
w0
p bSNP yjð ÞdbSNP .
cOR obtained from the adjusted logistic regression.
dp-value of the trend obtained from the adjusted logistic regression.
SNPs also selected by AUC-RF are bold-faced.
doi:10.1371/journal.pone.0083745.t002
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When focusing on AUC-RF results, 24 SNPs (ABCA1-rs2230806,
AICDA-rs2580874, ALOX5-rs1369214, BCL10-rs2647396, CD2-
rs3136701, CD4-rs2707210, FADD-rs7939734, FASLG-
rs929087, H2AFX-rs640603, H2AFX-rs643788, IKBKB-rs3747811,
IL15RA-rs2296135, IL21R-rs2189521, JAK3-rs2286662,
MAP2K4-rs4791489, MASP1-rs710459, NFKBIA-rs696, OPRD1-
rs204076, PRF1-rs10999426, RELA-rs11820062, RELA-
rs1466462, SCARB1-rs4765621, TBK1-rs10878178 and
TMED7-rs2052834) were identified in both datasets, represent-
ing the 43% and 27% of the SNPs selected in total and non-
smoker subjects, respectively.
Discussion
As all complex diseases, BC is not a single SNP/gene disorder.
Rather, many SNPs with small effects may lead to the
impairment of key pathways involved in their pathophysiology.
The identification of such SNP-signatures represents an an-
alytical challenge requiring the application of novel comprehen-
sive statistical approaches. To our knowledge, this is the first
study on BC analyzing a large number of SNPs with BTL that
has identified a subset of them jointly contributing to this
phenotype with a relevant magnitude of risk, much higher than
that provided by smoking (OR = 5 [2]), the main risk factor for
BC.
Thirteen SNPs in 13 genes were identified by both BTL and
AUC-RF, which can be considered as an internal validation. SNPs
in CASP3, IL6R, SCARB1, MAP2K4 and CD14_IK showed a
protective effect whereas those in PRF1, IL17R, ABCA1, MASP1,
TLR2, IL17C, FADD and ICAM1 were associated with a higher
risk of BC. Each SNP showed a small individual effect that could
not have been identified by logistic regression, the common
analytical approach used in GWAS, after applying the conserva-
tive Bonferroni’s correction for multiple testing.
We found previously published evidences about the association
of several of these SNPs/ genes with cancer risk despite the fact
that this information was not used in SNP selection. Among them,
SCARB1 codes for the scavenger receptor class B type I gene, a
cell-surface receptor that binds to high-density lipoprotein
cholesterol (HDL-C) and mediates HDL-C uptake [24,25].
SCARB1-rs4765621 maps to intron 1 and has been associated
with an increased risk of BC in combination with SLC23A2-
rs12479919, AKR1C3-rs2275928 and PLA2G6-rs2016755 [26].
This SNP is in linkage disequilibrium with SCARB1-rs4765623
that has been associated with renal cell carcinoma [27]. MAP2K4
encodes a dual specificity Ser/Thr protein kinase. Allelic
imbalances in this gene have been reported in bladder tumors
[28]. Furthermore, deletions and mutations of the MAP2K4 have
been described in human pancreatic, lung, breast, testicle, and
colorectal cancer cell lines, suggesting a tumor suppressor role
[29]. MAP2K4-rs4791489 is located 1226 bp downstream of the
gene and this is the first study to report an association with a
phenotype. IL7R encodes the receptor for IL-7, a cytokine
involved in the T cell differentiation and activation. IL7R variation
has been linked to chronic inflammatory diseases and cancer:
IL7R-rs1494555 has been associated with an increased risk of
gastric cancer [30], hematological neoplasms - by interacting
with a high BMI - [31], and non-small cell lung cancer where it
was detected by both logistic regression and random forest tests
[31]. This SNP leads to a Ile138Val substitution for which there
is no functional evidence. CD14 plays a major role in pathogen-
activated signal transduction pathways and in the production of
inflammatory cytokines [32]. CD14_IK-rs2569190 has been
associated with prostate cancer in African Americans [33],and
with coronary artery and cerebrovascular diseases [34,35].
PRF1 codes for perforin 1, one of the main toxic proteins of
cytolytic granules and a key effector in T-cell- and natural killer-
cell-mediated cytolysis. Its alterations cause familial hemopha-
gocytic lymphohistiocytosis type 2 (HPLH2), a rare and lethal
Figure 1. Histogram of the posterior probabilities of having a
positive (negative) SNP effect by Bayesian Threshold LASSO
model (BTL) in the total population. The dot point line indicates
the cut-off point of 80% above which SNPs were considered.
doi:10.1371/journal.pone.0083745.g001
Table 3. Relative variable importance for the top 12 polymorphisms selected by AUC-RF in the total population.
rs number Gene Type Alleles Position Relative variable importance a
rs2286662 JAK3 non synonymous coding A/G 19p13.11 20.8%
rs8192284 IL6R non_synonymous coding A/C 1q21.3 16.4%
rs7104333 CD5 downstream A/G 11q12.2 16.3%
rs288980 ROCK1 intronic C/T 18q11.2 15.7%
rs3087455 CASP3 intronic A/C 4q35.1 15.6%
rs11655650 BIRC5 intronic C/T 17q25.3 15.6%
rs3213427 CD4 3’ UTR T/C 12p13.31 15.3%
rs3136701 CD2 intronic C/G 1p13.1 15.0%
rs4765621 SCARB1 intronic G/A 12q24.31 14.8%
rs5498 ICAM1 coding unknown A/G 19p13.2 14.8%
rs2839488 TFF1 intronic C/G 21q22.3 14.6%
rs1937845 AKR1C3 5’ UTR G/A 10p15.1 14.4%
aCalculated by dividing the raw variable importance measurement by that with the highest MDG, that of smoking status.
doi:10.1371/journal.pone.0083745.t003
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Figure 2. Venn diagrams showing the overlapping between the SNPs selected by Bayesian Threshold model (BTL) and AUC-
Random Forest (AUC-RF). (A) Number of SNPs detected by each method in the total population. (B) Number of SNPs detected by each method in
the non-smoker subset. (C) Number of common SNPs detected by BTL in the total population and non-smoker subset, with posterior probabilities of
at least 80% and 75% of having an effect different from 0. (D) Number of SNPs detected by AUC-RF in both the total population and the non-smoker
subset.
doi:10.1371/journal.pone.0083745.g002
Table 4. Risk estimates from Bayesian Threshold LASSO model (BTL), considering a posterior probability of 75%, and from logistic
regression analyses among non-smokers.
rs number Gene Type Position Alleles ORaa_AA
a Post probb ORaa_AA
c p-valued
rs696 NFKBIA 3’ UTR 14q13.2 A/G 1.16 79.97 2.47 0.004
rs2647396 BCL10 intronic 1p22.3 C/T 0.89 79.65 0.40 0.011
rs10999426 PRF1 intronic 10q22.1 A/G 1.15 78.67 2.11 0.019
rs1800890 IL10 upstream 1q32.1 A/T 1.13 76.48 2.26 0.019
rs812606 MAP3K7 intronic 6q15 C/T 1.13 76.37 2.68 0.005
rs4791489 MAP2K4 downstream 17p12 C/T 0.91 76.87 0.49 0.030
rs20432 PTGS2 intronic 1q31.1 T/G 0.91 75.17 0.28 0.003
rs11188660 BLNK intronic 10q24.1 C/T 1.12 75.66 2.56 0.004
rs1061217 SLAMF1 3’ UTR 1q23.3 T/C 1.12 75.89 1.73 0.077
aPosterior mean of the OR, calculated from the BTL analyses. Similar values for the median were obtained for each SNP.
bIt corresponds to max a, 1{að Þf gw0:8, where a~
ðz?
w0
p bSNP yjð ÞdbSNP .
cOR obtained from the adjusted logistic regression.
dp-value of the trend obtained from the adjusted logistic regression.
SNPs also selected by AUC-RF are bold-faced.
doi:10.1371/journal.pone.0083745.t004
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autosomal recessive disorder of early childhood. PRF1-
rs10999426 has been clustered with other genes associated with
cytotoxic T cells in a colorectal cancer study: high expression of
the cytotoxic cluster genes was associated with a prolonged
disease-free survival [36]. Soluble interleukin-6-receptor-a-
subunit (IL-6R) is a potent cytokine playing an important role
in immune response. Altered gene expression has been
associated with multiple myeloma, autoimmune diseases and
prostate cancer risk [37]. The SNP IL6R-rs7529229, in linkage
disequilibrium with IL6R-rs8192284, has also been related to
risk of multiple myeloma [37].
We further focused on the assessment of non-smokers to discard
the potential modifying effect of tobacco on the association
between genetic variants and bladder cancer risk. Only two
polymorphisms associated with BC were detected by both
analytical methods: NFKBIA-rs696 and BCL10-rs2647396. NFKBI
is involved in response to stress, regulates COX-2 and proin-
flammatory cytokines, and is an important mediator of oncogen-
esis [38]. The NFKBIA-rs696 homozygosity has been associated
with a poorer survival in Swedish patients with colorectal cancer
[39]. Other studies have associated the deletion of NFKBIA with
glioblastoma multiforme [40] and Hodgkin’s lymphoma speci-
mens [41]. NFKBIA-rs696 is in linkage disequilibrium with rs8904,
a variant that has been associated with pain severity in lung cancer
patients [42]. BCL10, associated with protection from BC in our
study, plays an important role in the NF-kappaB and STAT
signalling pathways [40], It has been proposed to participate in
pancreatic carcinoma [43] and MALT lymphomas as part of the
t(1,4)(p22, q32) translocation [44]. BCL10-rs2647396 is intronic
and no function is known for this polymorphism.
Using an independent population and surrogate SNPs in high
LD with those identified in the discovery study, we replicated the
association with SNPs in IL6R and TBK1 identified by BTL. The
fact that the ORs obtained in the replication study were in
opposite direction to those detected in the discovery study can be
explained when using surrogate SNPs. Greene et al. recently
proved with simulated data that differences in allele frequency can
also provide an inversed allelic effect in a replication study [45].
When the threshold of the posterior probability was lowered to
70%, the association of five additional SNPs was also replicated.
Overall, we were able to replicate 30% of the selected SNPs by
BTL available in the TXBC study, a figure that is remarkable
when considering that BC is largely caused by environmental
factors and that both studies come from different geographical
areas and from centers with distinct patient referral patterns (in the
SBCS study most centers are general hospitals whereas the TXBC
Study was conducted at MD Anderson Cancer Center). Other
proposed causes for lack of replication are genetic heterogeneity,
environmental interactions, age-dependent effects, inadequate
statistical power, and gene-gene interactions, the latter explanation
pointing to a higher complexity of the underlying genetic
architecture [45]. We did not attempt to replicate SNPs identified
by AUC-RF because this method depends largely on the initial
variables considered. Woefully, data from a number of the original
SNPs considered in the discovery phase were not available in the
study used for replication.
The present study has several major strengths. Importantly, it
applies innovative analytical approaches dealing with the biolog-
ical complexity of the phenotype. Association analyses were
carried out by applying a regularized regression model (BTL) and
a nonparametric variable selection method (AUC-RF), in addition
to the single marker unconditional logistic regression, used in most
association studies. The first two methods overcome the main
limitation of the latter since they consider all the genetic
information jointly. The application of individual logistic regres-
sion makes sense under the assumption that only few genes affect
genetic predisposition [12], which certainly is not the case for BC.
BTL considers, a priori, that most of the SNPs have a small (if any)
effect on disease development, and performs a marker specific
shrinkage of effect estimates [20]. This approach permits dealing
with the ‘‘small n large p’’ problem and prevents overfitting. De los
Campos et al [22] suggested this method as an interesting
alternative to perform regressions on markers under an additive
model. We considered as associated to BC those SNPs with a
posterior probability .0.8 of having an effect greater (smaller)
than 0, as in [45]. Other criteria, as the Bayesian LOD score .3.2
[46] or ‘‘heritability of the marker’’.0.5% [47], have been used in
previous applications of BL. The choice of these criteria is
arbitrary because they have not been formally compared yet. On
the contrary, AUC-RF does not assume any model and considers
all possible interactions between the covariates included in the
analyses. It provides a measure of the importance of the variable,
although it does not indicate whether the effect of this variable is
protective or risky. It is also important to emphasize that the
selected variables with AUC-RF are not necessarily significantly
associated with the trait; rather, they represent the combination of
genotypes that best predicts the disease indicator and are thus
worthy of further investigation. We gave priority to those SNPs
selected by both methods although SNPs selected by only one of
them should not be discarded, given the different nature and
assumptions of each approach. Further methodological strengths
of the study are the large sample size, the high participation rates,
and the high quality of information on exposures and genotyping
of the SBC/EPICURO Study.
However, some limitations need to be considered when
interpreting these results. It is possible that potentially informative
susceptibility markers were not selected for genotyping. In
addition, incomplete tagging of the selected genes may have
resulted from the use of an earlier HapMap release to select tag
SNPs. Therefore, those genes with SNPs without relevant results in
this study should not be disregarded as potentially associated with
BC. As for the constraints of the approaches used, BTL only
assumes an additive mode of inheritance and no interactions were
considered. A common drawback of machine learning based
methods, such as AUC-RF, is that they typically identify a SNP set
that produces the highest classification accuracy but does not
necessarily correspond to a strong association with the disease.
Indeed, machine learning-based approaches tend to introduce
false positives, since the inclusion of many SNPs increases
classification accuracies [48].
The large difference in the risk estimates according to BTL
between the total and the non-smoker datasets suggests a potential
modifying effect of tobacco over the SNP-signature on BC risk.
While statistical underpowered results cannot be discarded, a large
smoking*SNPs interaction assessment considering all SNPs
included in the study should be performed. This analysis requires
of further methodology innovation and large computational
infrastructure.
In conclusion, we report here the joint effect of several variants
in inflammatory genes strongly associated with BC risk. The use of
multi-SNP assessment approaches to explore the hidden herita-
bility of complex diseases is highly promising in the association
analysis field. While the application of these methods at a genome-
wide level is straightforward, the great computational demand
represents the main constraint and few studies have applied them
to genome-wide data in association [15] or prediction settings [49]
till present. Ours is one of the first studies applying such
methodologies to a large set of SNPs in cancer research.
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Materials and Methods
Ethics statement
Informed written consent was obtained from the study
participants. The study was approved by the Institutional Review
Board of the U.S. National Cancer Institute, the Ethics
Committees of each participating hospital, MD Anderson Cancer
Center, and the Baylor College of Medicine.
Study population
The population considered in this analysis comes from the
Spanish Bladder Cancer/EPICURO Study. This is a hospital-
based case-control study conducted during 1998–2001 in 18
hospitals in five areas in Spain (Asturias, Barcelona metropolitan
area, Valle`s/Bages, Alicante and Tenerife), as described elsewhere
[50]. Eligible cases were aged 21–80 years and newly diagnosed of
a histologically confirmed transitional cell carcinoma of the
urinary bladder based on the 1998 system of WHO and the
International Society of Urological Pathology [51]. Controls were
selected from patients admitted to participating hospitals for
diagnoses thought to be unrelated to the BC risk factors, and
individually matched to the cases on age at interview within 5-year
categories, gender, ethnicity and region. A total of 1,451 cases and
1,444 controls were eligible for the study, out of them 84% of the
cases and 88% of the controls agreed to participate and were
interviewed.
Demographic and risk factor information was collected at the
hospital using computer-assisted personal interviews. Subjects
were categorized regarding smoking status as never smokers, if
they had smoked less than 100 cigarettes in their lifetime;
occasional smokers, if they had smoked at least one cigarette per
day for less than 6 months; former smokers, if they had smoked
regularly but stopped smoking more than one year before the
study inclusion date; and current smokers, if they had smoked
regularly within a year of the inclusion date.
A very large proportion of individuals, 1,188 cases and 1,173
controls, provided blood or buccal cell sample for DNA extraction.
Gene & SNP selection and genotyping
A 1,536 SNPs GoldenGate Illumina Genotyping Assay (San
Diego, CA, USA) platform was designed using tagSNPs selected to
cover the variation of key genes involved in candidate pathways,
among them those related to inflammatory response (see Table
S5). Genes were carefully selected according to current available
evidence, both epidemiological and biological, of their involve-
ment in inflammatory processes. Gene selection favored those
inflammatory genes showing association with cancer. The
selection of tagSNPs was done using the SYSNPs (Select Your
SNPs) application [52]. At the moment of tagSNPs selection, the
available databases were dbSNP b25, hg17 and HapMap Release.
The tagger algorithm was Haploview’s Tagger (v3.32) with default
parameter values. SYSNPs options were selected to force the
inclusion of SNPs that had been previously genotyped in the same
samples as tagSNPs. These previous genotyping efforts are
described in detail in Garcia-Closas [50,53] for the TaqMan
and a previous GoldenGate Illumina genotyping, respectively.
SNPs were genotyped following the manufacturer’s instructions
(http://www.illumina.com/) regarding DNA amount and con-
centrations and by including intra- and inter-assay duplicates as
well as negative controls. DNA from cases and controls was blindly
placed in the 96-well plates so that proportionate numbers were
achieved in all plates. Successful genotyping was obtained for
1,150 cases and 1,149 controls.
Quality control
Following the recommendations of Anderson, Pettersson et al.
[54], a thorough assessment of data quality was carried out. SNPs
(N = 15) genotyped in the present and previous platforms showed
good agreement (ranging from 98.2% to 99.8%); thus, individuals
with missing SNPs data in one platform were completed with their
counterparts from the same SNP genotyped in the other platforms,
if they were no missing. To consider individuals in this analysis, we
required that .95% of the SNPs were successfully genotyped in
each platform. In addition, SNPs showing .5% missing geno-
types, and those with a MAF ,5% that did not show an
association with BC after performing a Fisher’s exact test, were
excluded from the analyses. The final number of cases and
controls included in the analysis was 1,047 and 988, respectively.
Missing genotypes were imputed with the k-NN method using the
package SCRIME in R [55]. To minimize colinearity between
variables, pairwise linkage disequilibrium between SNPs was
estimated based on r2 values using the package GENETICS in
R (http://cran.r-project.org/web/packages/genetics/index.html),
and only one of each pair of SNPs were retained for further
analyses when r2.0.8. In addition, those SNPs pertaining to the X
chromosome (24 SNPs belonging to 7 genes) were excluded from
the final dataset, yielding a final number of 886 SNPs and 194
genes. The existence of population stratification was also checked
using a principal component analysis. While participants were
selected from different regions of Spain, no subpopulations were
apparent after the visual inspection of the first two principal
components.
Statistical methods
Three different statistical approaches were applied to explore
the association of SNP variants with BC risk: the Bayesian
Threshold Lasso model (BTL), the Area Under the Curve-
Random Forest (AUC-RF), and the logistic regression applied to
each individual SNP.
Bayesian Threshold LASSO model. A BTL model [45]
was adapted in this study for the association analysis. A threshold
model [56] was considered to account for the discrete nature of the
phenotype (y), which can take the values 0 or 1, if the individual
did not show or showed the disease, respectively. This method-
ology assumes that the expression of the trait is related to an
underlying continuous variable, called liability (l) [57], so that the
disease is observed if the value of the latent variable exceeds a
threshold (t). This can be expressed as follows:
Pr yi~1 hj ,s2e
 
~Pr tj{1vli be,bSNP,t,s2e
 
~1{W
t{x
0
ei
be{x
0
SNPi
bSNP
s2e
 ! ð1Þ
where s2e corresponds to the residual variance, be is the vector of
environmental (non-genetic) covariate effects (i. e., gender;
smoking status in 4 categories; region, in 5 categories; and age
as a continuous covariate), bSNP is the vector of the coefficients of p
SNPs in inflammation related genes, and x
0
ei
and x
0
SNPi
correspond
to the incidence vectors of appropriate order. Thus, the following
model was assumed for the liabilities li~x
0
ei
bezx
0
SNPi
bSNPzei.
An additive inheritance model was assumed for the SNPs, so that
they were coded as 0, 1 and 2 if the genotype was AA, Aa and aa,
respectively.
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LASSO method [19] simultaneously perform variable selection
and shrinkage of coefficients. The Bayesian interpretation of the
LASSO [20] indicates that the solution can be viewed as the
posterior mode in a Bayesian model with Gaussian likelihood
p y b,s2e
 ~ Pn
i~1
N yi x
0
ib,s
2
e
  and a prior on b that is the product
of m independent, zero-mean, double exponential (DE) densities
DE bj lj
 
~
l
2
e{l bjj j. DE prior can be represented as a mixture of
scaled Gaussian densities, where the mixing process of the
variances is an exponential distribution (P
m
j~1
N bj 0,t
2
j s
2
e
 |
P
m
j~1
exp t2j lj
 
). Parameter l controls the shape of the prior
distribution assigned to t{2j , the exponential prior assigns more
density to small values of the tj than to large ones, and follows, a
priori, a Gamma distribution G l2 a1,a2j
 
. A DE prior produces
stronger shrinkage of regression coefficients close to 0 (without an
effect) and less shrinkage to those with large absolute values.
Fully conditional distribution for unknowns (i.e., regression
coefficients (b), t{2j and l
2) were multivariate normal with
mean (covariance matrix) equal to the solution (inverse of
coefficient matrix) of the system of equations
X
0
Xs{2e zDiag t
{2
j s
{2
e
 h i
b^~X
0
ys{2e , inverse Gaussian with
mean mj~ sel

bj
   and scale parameter l2, and Gamma
pza,
1
2
Xp
j~1
t2jza2
 	
, respectively. The residual variance
and the threshold separating the two categories (controls and
cases) were set to 1 and 0 for identification purposes.
For each analysis, a unique McMC chain of 50,000 iterations
was obtained using a Gibbs sampler implemented in the Fortran-
language [45]. The first 10,000 iterations were discarded as burn-
in and all the remaining iterations were retained to infer posterior
marginal distributions of unknown parameters. Convergence of
chains was assessed visually and applying the Geweke criterion
[58]. SNPs were considered to be associated with BC when the
mass of the marginal posterior distribution of the coefficient was
far from the null hypothesis being equal to zero, specifically, when
max a, 1{að Þf gw0:8, where a is the area from zero to infinity
under the marginal posterior distribution of the coefficient:
a~
ðz?
w0
p bSNP yjð ÞdbSNP.
Posterior distributions of odds ratios (OR) for each SNP were
calculated as a measure of relative risk. First, the probability of
having BC for each genotype at each iteration was calculated by
transforming the liability to BC to the observable scale, following
Dempster and Lerner [59]. Thus, the probability of having BC for
individuals with genotype AA for the SNP s at iteration (k) was
calculated as:
Pr yi~1 b
(k)
s ,m,s
2
e
 ~1{W t{m{xAAb(k)s
se
 !
ð2Þ
where m corresponds to the mean of the liability to BC. OR
posterior distributions for each SNP were calculated considering
the AA genotype as the reference group. For example, the odds of
disease for individuals with the heterozygous genotype compared
with those individuals with the AA genotype (OR
(k)
j~Aa AAj ) at
iteration k was calculated as:
OR
(k)
s~Aa AAj ~
Pr yi~1 xAab
(k)
s
 Pr yi~0 xAab(k)s 
Pr yi~1 xAAb
(k)
s
 Pr yi~0 xAAb(k)s  ð3Þ
In addition, the OR posterior distributions corresponding to the
signature of the SNPs detected by BTL were calculated using a
modification of equation (3):
OR
(k)
risky=protective~
Pr yi~1 Xriskyb
(k)
 Pr yi~0 Xriskyb(k) 
Pr yi~1 Xprotectiveb
(k)
 Pr yi~0 Xprotectiveb(k) 
ð4Þ
where Xriskyb
(k)/ Xprotectiveb
(k) corresponds to the effect of the
most risky/protective genotypes of the SNPs detected as relevant
by BTL at iteration k.
Area Under the Curve-Random Forest. Recently Calle
et al. [16] proposed a new algorithm for genomic profiling based
on optimizing the area-under-the ROC curve (AUC) of the
Random Forest [13]. Briefly, RF comprises an ensemble of trees,
generated from bootstrap samples, and their application provides
a quantification of the variable importance in the context of a
non-linear model. AUC-RF algorithm iteratively fits RF and
performs a backward elimination process based on the initial
ranking of variables. The area under the ROC curve (AUC) of
the RF is used instead of the classification error as a measure of
predictive accuracy. Five hundred trees were used to construct
each forest, a 20% of variables were eliminated at every step and
the number of remaining variables to stop the process of
backward elimination was set to 10. The optimizing criterion
used to construct the trees was the mean decrease Gini index
(MDG), and the relative variable importance of each variable
was calculated by dividing the raw variable importance
measurement (i.e., the MDG) by that with the highest MDG.
In order to perform a more fair comparison with the results
obtained from BTL model, environmental effects were also
included in the AUC-RF analyses. Age, recorded as a continuous
variable, was categorized in 3 groups: ,60 yr; 60–70 yrs; and $
70 yrs, to avoid bias [60]. AUC-RF was implemented using the
AUCRF package [16] in R- language (http://www.R-project.
org).
Logistic regression. The standard approach in most GWAS
was also used to analyze the association between BC and the
individual SNPs belonging to genes related to inflammation. Odds
ratios and p-values for the common homozygous versus the rare
homozygous were calculated for each SNP using an unconditional
logistic regression. Environmental covariates (e. g., age, region,
smoking status and gender) were included in the model in order to
adjust by their potential confounding effects. Analyses were run in
R-language (http://www.R-project.org). Those SNPs with p-
values ,0.05, two-sided test, after Bonferroni’s correction were
kept for comparison with the results of the other two methods.
The number of SNPs detected by both BTL and AUC-RF in
the total population and the non-smoker subset was examined, as
well as the corresponding p-value obtained after the logistic
regression. Analyses were also run among non-smokers to clean
Multi-SNP Assessment of Bladder Cancer Risk
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e83745
the population up for the smoking effect, the main environmental
risk factor. It has been previously suggested that the genetic
architecture of this group is different from that among smokers [16].
Those SNPs detected by the two first methods both in the total
population and in the non-smokers subset were further discussed.
Replication study
Cases and controls in the replication stage were from the Texas
Bladder Cancer (TXBC) study, a hospital-based bladder cancer
case–control study conducted at the University of Texas MD
Anderson Cancer Center. All cases were newly diagnosed,
histologically confirmed, and previously untreated incident blad-
der cancer cases recruited from 1999 until present [5]. The
controls were healthy individuals with no prior history of cancer
(except non-melanoma skin cancer) and were recruited from
Kelsey Seybold, the largest multi-specialty, managed-care physi-
cian group in the Houston metropolitan area.
Trained MD Anderson interviewers collected comprehensive
epidemiological data in a 45 minute interview on demographics,
family history of cancer, and smoking status from all study
participants of the TXBC study. Most (78.2%) of cases and sex-
matched controls were men. The mean age of cases (63.8 years)
and controls (62.9 years) was highly similar. As expected, the
percentage of smokers among cases was higher than that among
control: 73% vs. 55%, respectively. Blood sample was collected for
DNA extraction at the end of the interview.
Genomic DNA extraction and storage was described elsewhere
[5]. Genotyping for the TXBC data set was generated using the
Illumina HumanHap610 chip containing 620,901 markers and
the iSelect chip containing 9,645 SNPs at MD Anderson.
Detailed quality control measures were described previously. All
the subjects included in this study were Caucasians and had call
rate .95%. A total number of 695 cases and 706 controls were
considered for analysis. SNP call rate .95% criterion was
applied. We further removed markers that deviated from Hardy-
Weinberg equilibrium in the controls at p-value , 0.0001. Out of
886 SNPs considered in the discovery study, 372 SNPs were
available from the TXBC study and passed quality control
procedures. Among them, 17 SNPs overlapped with those
selected by the BTL method in the SBC/EPICURO Study.
We further included 13 SNPs from the TXBC study that were in
high LD with SNPs detected in the discovery study. The BTL
model included all SNPs as well as gender, age, and smoking
status. The analyses were performed with the same software and
criteria in both studies.
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Figure S1 Posterior distribution of the OR correspond-
ing to the 37 SNP-signature detected by BTL in the total
population (calculated using equation 4). The minimum
estimate for OR was 4.92. The 95% credible interval for the ORs
corresponding to the 37 SNPs-signature ranged 31.15-629.42 with
the most risky genotype combination conferring 123.5 (posterior
median) fold higher risk of BC than the most protective one. The
wide 95% interval indicates a large error associated to the
estimation of the OR for the 37 SNPs-signature.
(DOCX)
Figure S2 Log OR median (bullets) and 95% credible
intervals (vertical lines) for the signatures including the
SNPs with the highest posterior probabilities from BTL
analysis on total data. Note that the higher number of SNPs
included in the signature the wider is the 95% credible interval
(error associated to the estimate of OR).
(DOCX)
Figure S3 Posterior distribution of the OR correspond-
ing to the 9 SNP-signature detected by BTL (75%
posterior probability cut-off point) in the non-smoker
subset. Note that the 95% credible interval is narrower than that
for the OR of the SNP-signature for the total population (Figures
S1 and S2), probably due to the lower number of SNPs included in
that signature.
(DOCX)
Table S1 Genotype distribution among cases and
controls and bladder cancer risk estimates for the SNPs
with p-values ,0.05 obtained in the single marker
analyses.
(DOCX)
Table S2 Relative variable importance for the polymor-
phisms selected by AUC-RF in the total population.
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Table S3 Risk estimates and posterior probabilities of
having an effect larger (smaller) than 0 of the SNPs
included in the validation study that are in common (or
in high LD) with those detected in the discovery study by
BTL.
(DOCX)
Table S4 Relative variable importance for the SNPs
selected by AUC-RF among the non-smoker population.
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Table S5 Top 50 gene sets of canonical pathways and
GO biological process (http://www.broadinstitute.org/
gsea) with the rate of overlapping with the gene set used
in this study.
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